Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Apellis Pharmaceuticals stock last closed at $49.86, up 4.03% from the previous day, and has decreased 41.12% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Apellis Pharmaceuticals stock is currently +151.44% from its 52-week low of $19.83, and -47.38% from its 52-week high of $94.75.
As of Apr 26, 2024, there are 120.58M shares of APLS outstanding. The market cap of APLS is $6.01B. In the last 24 hours, 980,419 APLS shares were traded.
You need a brokerage account in order to access the NASDAQ market and buy APLS stock.
We believe that eToro is the best brokerage. Here's why:
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountNow that you've selected the right brokerage, you'll need to fill out some personal info so you can buy APLS stock today.
Now that you have finished signing up on the best stock app for beginners, you need to deposit funds:
Watch the walkthrough below for more details depositing funds into your new investment account.
After you have decided on the best place to buy Apellis Pharmaceuticals stock, it's crucial to evaluate their stock prior to buying, so you can wrap your head around the risk and opportunity.
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on APLS's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge APLS's fair value.
Using relative valuations methods:
You can access additional valuation research on APLS's stock here.
Out of 14 sell side analysts who give ratings on APLS, the consensus analyst rating on APLS is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Eliana Merle, a top 21% analyst from UBS maintains APLS with a strong buy rating and raises their APLS price target from $87.00 to $89.00, on Mar 4, 2024.
UBS's Eliana Merle raised their price target on Apellis Pharmaceuticals (NASDAQ: APLS) by 2.3% from $87 to $89 on 2024/03/04. The analyst maintained their Strong Buy rating on the stock.
Harkening back to Apellis Pharmaceuticals' Q4 and FY 2023 earnings, reported on 2024/02/27, Merle said that "management's color on Q1 2024 sales trends increases UBS's conviction in the ongoing Geographic Atrophy commercial launch and their firm expects continued revenue growth in Q1 and beyond."
Apellis Pharmaceuticals is a revenue growth story from here, the analyst argued, saying they see "additional potential upside for the stock from Phase 3 C3 glomerulopathy/immune-complex membranoproliferative glomerulonephritis topline data, expected in mid-2024."
Colleen Kusy, a bottom 4% analyst from Baird reiterates APLS with a buy rating and maintains their APLS price target from $81.00 to $81.00, on Feb 6, 2024.
Akash Tewari, a top 28% analyst from Jefferies upgrades APLS to a strong buy rating and raises their APLS price target from $68.00 to $80.00, on Feb 5, 2024.
Justin Kim, a top 23% analyst from Oppenheimer maintains APLS with a buy rating and raises their APLS price target from $75.00 to $79.00, on Jan 30, 2024.
Steven Seedhouse, a top 11% analyst from Raymond James maintains APLS with a strong buy rating and raises their APLS price target from $67.00 to $106.00, on Jan 11, 2024.
You can dig deeper into what analysts are forecasting on the Apellis Pharmaceuticals stock forecast page.
Last year, APLS revenue was $396.59M. In the last 3 year, APLS's revenue has gone up by 83.5% per year. This was faster than the Biotechnology industry average of 28.56%.
You can research APLS's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at APLS have bought more shares than they have sold.
A. Sinclair Dunlop, Director of APLS, was the latest APLS insider to buy. They bought $19,785.00 worth of APLS stock on Apr 12, 2024.
Research more about who owns APLS shares here.
No, Apellis Pharmaceuticals doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two primary order types:
Click the Open button and eToro will execute your order.
If you need more help buying stocks on eToro, click the helpful video below:
Now that you own some shares in APLS, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to keep tabs on your APLS stock.
To reiterate, here are the 6 steps you need to take to buy Apellis Pharmaceuticals stock right now:
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your new investment in Apellis Pharmaceuticals, click the button below.